These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. SGLT-2 inhibitors in chronic peritoneal dialysis patients: a follow-up study. Lai JW; Wang CCN; Chou CY BMC Nephrol; 2024 Jul; 25(1):238. PubMed ID: 39075357 [TBL] [Abstract][Full Text] [Related]
63. Sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in real-world clinical practice? A systematic review and meta-analysis of observational studies. Hinton W; Ansari AS; Whyte MB; McGovern AP; Feher MD; Munro N; de Lusignan S Diabetes Obes Metab; 2023 Feb; 25(2):501-515. PubMed ID: 36239122 [TBL] [Abstract][Full Text] [Related]
64. Renal outcomes and all-cause death associated with sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL 3 Korea). Koh ES; Han K; Nam YS; Wittbrodt ET; Fenici P; Kosiborod MN; Heerspink HJL; Yoo SJ; Kwon HS Diabetes Obes Metab; 2021 Feb; 23(2):455-466. PubMed ID: 33118320 [TBL] [Abstract][Full Text] [Related]
65. Glucose-Lowering Medications and Post-Dementia Survival in Patients with Diabetes and Dementia. Secnik J; Xu H; Schwertner E; Hammar N; Alvarsson M; Winblad B; Eriksdotter M; Garcia-Ptacek S; Religa D J Alzheimers Dis; 2022; 86(1):245-257. PubMed ID: 35034902 [TBL] [Abstract][Full Text] [Related]
66. Hormonal, Metabolic and Hemodynamic Adaptations to Glycosuria in Type 2 Diabetes Patients Treated with Sodium-Glucose Co-Transporter Inhibitors. Cersosimo E; Miles JM Curr Diabetes Rev; 2019; 15(4):314-327. PubMed ID: 30101716 [TBL] [Abstract][Full Text] [Related]
67. Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community. Nelson AJ; Pagidipati NJ; Aroda VR; Cavender MA; Green JB; Lopes RD; Al-Khalidi H; Gaynor T; Kaltenbach LA; Kirk JK; Lingvay I; Magwire ML; O'Brien EC; Pak J; Pop-Busui R; Richardson CR; Reed M; Senyucel C; Webb L; McGuire DK; Granger CB Circulation; 2021 Jul; 144(1):74-84. PubMed ID: 34228476 [TBL] [Abstract][Full Text] [Related]
68. Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) Reduce Hospitalization for Heart Failure Only and Have No Effect on Atherosclerotic Cardiovascular Events: A Meta-Analysis. Sinha B; Ghosal S Diabetes Ther; 2019 Jun; 10(3):891-899. PubMed ID: 30875065 [TBL] [Abstract][Full Text] [Related]
69. Do SGLT-2 inhibitors exhibit similar cardiovascular benefit in patients having reduced ejection fraction heart failure with type 2 diabetes, prediabetes and normoglycemia? Singh AK; Singh R Diabetes Metab Syndr; 2021; 15(6):102282. PubMed ID: 34562869 [TBL] [Abstract][Full Text] [Related]
70. Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease. Mao X; Zhang X; Kam L; Chien N; Lai R; Cheung KS; Yuen MF; Cheung R; Seto WK; Nguyen MH Gut; 2024 Aug; ():. PubMed ID: 39122360 [TBL] [Abstract][Full Text] [Related]
71. Role of Sodium-Glucose Cotransporter-2 Inhibition in the Treatment of Adults With Heart Failure. Sharma A; Ezekowitz JA Can J Diabetes; 2020 Feb; 44(1):103-110. PubMed ID: 31630988 [TBL] [Abstract][Full Text] [Related]
72. Effects of Sodium-Glucose Cotransporter-2 Inhibitors and Thiazolidinedione on New-Onset Atrial Fibrillation Risk to Patients with Type 2 Diabetes. Song H; Kim YR; Lee SE; Nam H; Kim H; Kyoung DS; Kim KA Rev Cardiovasc Med; 2022 Sep; 23(9):303. PubMed ID: 39077692 [TBL] [Abstract][Full Text] [Related]
73. Drug-Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data. Alkabbani W; Pelletier R; Beazely MA; Labib Y; Quan B; Gamble JM Drug Saf; 2022 Mar; 45(3):287-295. PubMed ID: 35247195 [TBL] [Abstract][Full Text] [Related]
74. SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. Shi N; Shi Y; Xu J; Si Y; Yang T; Zhang M; Ng DM; Li X; Xie F Front Public Health; 2021; 9():668368. PubMed ID: 34164370 [No Abstract] [Full Text] [Related]
75. Sodium-glucose cotransporter-2 inhibitors protect against atrial fibrillation in patients with heart failure. Zhou L; Yang Y; Han W Ann Palliat Med; 2021 Oct; 10(10):10887-10895. PubMed ID: 34763450 [TBL] [Abstract][Full Text] [Related]
76. The effect of SGLT-2i administration on red blood cell distribution width in patients with heart failure and type 2 diabetes mellitus: A randomized study. Katsiadas N; Xanthopoulos A; Giamouzis G; Skoularigkis S; Skopeliti N; Moustaferi E; Ioannidis I; Patsilinakos S; Triposkiadis F; Skoularigis J Front Cardiovasc Med; 2022; 9():984092. PubMed ID: 36247420 [TBL] [Abstract][Full Text] [Related]
77. SGLT-2 Inhibitors in Heart Failure and Type-2 Diabetes: Hitting Two Birds with One Stone? Santos-Ferreira D; Gonçalves-Teixeira P; Fontes-Carvalho R Cardiology; 2020; 145(5):311-320. PubMed ID: 31865310 [TBL] [Abstract][Full Text] [Related]
78. Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies. Caruso I; Cignarelli A; Sorice GP; Natalicchio A; Perrini S; Laviola L; Giorgino F Metabolites; 2022 Feb; 12(2):. PubMed ID: 35208256 [TBL] [Abstract][Full Text] [Related]
79. The anti-inflammatory and immunological properties of SGLT-2 inhibitors. Bendotti G; Montefusco L; Pastore I; Lazzaroni E; Lunati ME; Fiorina P J Endocrinol Invest; 2023 Dec; 46(12):2445-2452. PubMed ID: 37535237 [TBL] [Abstract][Full Text] [Related]
80. Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies. Singh AK; Singh R Expert Rev Clin Pharmacol; 2019 Apr; 12(4):299-308. PubMed ID: 30817235 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]